Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study



Kosiborod, Mikhail, Lam, Carolyn SP, Kohsaka, Shun, Kim, Dae Jung, Karasik, Avraham, Shaw, Jonathan, Tangri, Navdeep, Goh, Su-Yen, Thuresson, Marcus, Chen, Hungta
et al (show 58 more authors) (2018) Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. Journal of the American College of Cardiology, 71 (23). 2628 - 2639.

Access the full-text of this item by clicking on the Open Access link.

Abstract

Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe. Objectives The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Pacific, the Middle East, and North American regions. Methods New users of SGLT-2i and oGLDs were identified via claims, medical records, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, MI, and stroke were assessed by country and pooled using weighted meta-analysis. Results After propensity-matching, there were 235,064 episodes of treatment initiation in each group; ∼27% had established CV disease. Patient characteristics were well-balanced between groups. Dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin, and luseogliflozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of exposure time in the SGLT-2i group, respectively. Use of SGLT-2i versus oGLDs was associated with a lower risk of death (HR: 0.51; 95% confidence interval [CI]: 0.37 to 0.70; p < 0.001), HHF (HR: 0.64; 95% CI: 0.50 to 0.82; p = 0.001), death or HHF (HR: 0.60; 95% CI: 0.47 to 0.76; p < 0.001), MI (HR: 0.81; 95% CI: 0.74 to 0.88; p < 0.001), and stroke (HR: 0.68; 95% CI: 0.55 to 0.84; p < 0.001). Results were directionally consistent across both countries and patient subgroups, including those with and without CV disease. Conclusions In this large, international study of patients with T2D from the Asia Pacific, the Middle East, and North America, initiation of SGLT-2i was associated with a lower risk of CV events across a broad range of outcomes and patient characteristics. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614)

Item Type: Article
Additional Information: publisher: Elsevier articletitle: Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs journaltitle: Journal of the American College of Cardiology articlelink: https://doi.org/10.1016/j.jacc.2018.03.009 content_type: article copyright: © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
Uncontrolled Keywords: death, diabetes mellitus, heart failure, observational studies, sodium glucose cotransporter-2 inhibitors, SGLT-2 inhibitor
Depositing User: Symplectic Admin
Date Deposited: 20 Jul 2018 10:20
Last Modified: 14 May 2021 13:10
DOI: 10.1016/j.jacc.2018.03.009
Open Access URL: https://onlinelibrary.wiley.com/doi/epdf/10.1111/d...
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3023980